La Roche-Posay is the first brand recommended by dermatologists in Canada, and now offers its first-ever safety guarantee on two of its products for atopic, eczema prone newborns. The brand’s Lipikar AP+ and Lipikar Syndet AP+ products are clinically proven to be safe to use from the first day of life.
Emma Kindler, general manager, La Roche-Posay Canada, says, "We pride ourselves on making no compromise on efficacy or safety, and this new claim strengthens our commitment with a new emblematic safety guarantee for newborns, especially those with atopic eczema-prone skin. Now families across Canada can feel confident using Lipikar Baume AP+ or Lipikar Syndet AP+ on their babies…”
In clinical tests, the products have shown significant tolerance results on children and babies. Both products have been tested on newborns, in a clinical study, and under pediatric control, proving their optimal safety. (The study, “Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention” was published in the Journal of Allergy and Clinical Immunology, vol 134, no 4.)
Additional clinical studies have demonstrated that using emollients as the first three weeks of life reduces the risk of developing eczema-prone skin. (This was an internal study conducted on 40 newborns, 0 - 1-month-old, under dermatologic and pediatric control, with one dedicated evaluation per product. The product was applied to face and body at least once a day for four weeks.)
Atopic eczema is a chronic inflammatory skin disease that has reached epidemic proportion in children worldwide and is increasing in prevalence. Children suffering from this condition, experience unbearable itch along with inflamed, cracked, and often infected skin lesions.
The LIPIKAR AP+ products, shown above, are formulated to soothe and calm atopic eczema-prone skin. The products have lipid-replenishing, anti-irritation, anti-scratching, and anti-itch properties.